Ex­clu­sive: No­vo foun­da­tion's growth arm is mak­ing an in­vest­ment push in­to health­care, ex­pand­ing be­yond life sci­ences

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.) 

No­vo Hold­ings, the in­vest­ment arm of No­vo Nordisk’s par­ent foun­da­tion, is mak­ing a push in­to health­care through its growth in­vest­ing arm, with a fo­cus on mak­ing sig­nif­i­cant bets on med­ical tech­nol­o­gy and health­care ser­vices com­pa­nies.

The foun­da­tion’s as­sets have swollen thanks to the block­buster suc­cess of drug­mak­er No­vo Nordisk’s GLP-1 prod­ucts for weight loss and di­a­betes. No­vo Hold­ings man­ages the as­sets of the foun­da­tion, which has stakes in the phar­ma­ceu­ti­cal gi­ant No­vo Nordisk as well as Novozymes. It al­so in­vests in life sci­ences com­pa­nies and oth­ers with the aim of gen­er­at­ing re­turns for the foun­da­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.